Donald Fong

Donald Fong

Company: Annexon Biosciences

Job title: Vice President, Ophthalmology Clinical Development


Spotlight on ANX007 – Inhibition of C1q for GA 11:45 am

Discuss rationale for chronic classical complement activation as a driver of GA Assess potential advantages of selective, local inhibition of C1q for regulating complement activity in GA Review Phase 1 safety and target engagement with ANX007 Provide update on ARCHER, the ongoing Phase 2 study of ANX007 in GARead more

day: Track 2 Day 1 AM

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.